 Aloka Patel
Concepts (217)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Milk, Human | 23 | 2019 | 127 | 8.770 |
Why?
| | Infant, Very Low Birth Weight | 21 | 2019 | 137 | 6.920 |
Why?
| | Breast Feeding | 15 | 2019 | 108 | 5.250 |
Why?
| | Intensive Care Units, Neonatal | 24 | 2018 | 168 | 5.150 |
Why?
| | Infant, Premature | 26 | 2018 | 183 | 4.540 |
Why?
| | Mothers | 10 | 2018 | 118 | 4.100 |
Why?
| | Infant, Newborn | 37 | 2019 | 594 | 3.290 |
Why?
| | Lactation | 8 | 2018 | 62 | 3.120 |
Why?
| | Enterocolitis, Necrotizing | 9 | 2017 | 26 | 2.870 |
Why?
| | Patient Discharge | 5 | 2018 | 94 | 2.360 |
Why?
| | Milk Banks | 5 | 2019 | 20 | 2.210 |
Why?
| | Child Development | 5 | 2019 | 67 | 2.020 |
Why?
| | Infant, Premature, Diseases | 3 | 2017 | 22 | 1.510 |
Why?
| | Intensive Care, Neonatal | 5 | 2019 | 31 | 1.490 |
Why?
| | Breast Milk Expression | 8 | 2018 | 43 | 1.360 |
Why?
| | Infant Nutritional Physiological Phenomena | 7 | 2018 | 46 | 1.310 |
Why?
| | Goals | 3 | 2017 | 45 | 1.180 |
Why?
| | Bronchopulmonary Dysplasia | 3 | 2016 | 14 | 1.120 |
Why?
| | Infant | 11 | 2018 | 533 | 1.060 |
Why?
| | Gestational Age | 10 | 2018 | 85 | 1.040 |
Why?
| | Infant Care | 3 | 2016 | 22 | 1.000 |
Why?
| | Infant Formula | 2 | 2019 | 16 | 0.990 |
Why?
| | Continental Population Groups | 3 | 2016 | 94 | 0.980 |
Why?
| | Enteral Nutrition | 2 | 2017 | 48 | 0.980 |
Why?
| | Female | 32 | 2019 | 14317 | 0.960 |
Why?
| | Health Care Costs | 3 | 2016 | 69 | 0.950 |
Why?
| | Social Support | 2 | 2017 | 171 | 0.920 |
Why?
| | Humans | 41 | 2019 | 24300 | 0.910 |
Why?
| | Health Knowledge, Attitudes, Practice | 5 | 2017 | 181 | 0.870 |
Why?
| | Nervous System | 1 | 2017 | 14 | 0.860 |
Why?
| | Prospective Studies | 10 | 2017 | 1372 | 0.850 |
Why?
| | Infant, Low Birth Weight | 1 | 2017 | 15 | 0.850 |
Why?
| | Pregnancy in Adolescence | 1 | 2017 | 9 | 0.840 |
Why?
| | Maternal Behavior | 1 | 2017 | 14 | 0.840 |
Why?
| | Quality of Health Care | 1 | 2017 | 116 | 0.750 |
Why?
| | Informed Consent | 1 | 2015 | 23 | 0.750 |
Why?
| | Quality Improvement | 1 | 2017 | 111 | 0.740 |
Why?
| | Bacteria | 1 | 2016 | 61 | 0.740 |
Why?
| | Gastrointestinal Tract | 1 | 2016 | 47 | 0.740 |
Why?
| | Mother-Child Relations | 1 | 2015 | 38 | 0.730 |
Why?
| | Sepsis | 2 | 2017 | 132 | 0.730 |
Why?
| | Hospitalization | 3 | 2016 | 236 | 0.710 |
Why?
| | Birth Weight | 5 | 2017 | 41 | 0.710 |
Why?
| | Residence Characteristics | 1 | 2016 | 184 | 0.700 |
Why?
| | Male | 25 | 2019 | 14071 | 0.690 |
Why?
| | Decision Making | 1 | 2015 | 162 | 0.670 |
Why?
| | Educational Status | 4 | 2018 | 226 | 0.600 |
Why?
| | Oxygen | 2 | 2003 | 78 | 0.580 |
Why?
| | Pregnancy | 3 | 2017 | 313 | 0.570 |
Why?
| | Sleep | 2 | 2003 | 253 | 0.480 |
Why?
| | Infant, Extremely Low Birth Weight | 3 | 2017 | 20 | 0.470 |
Why?
| | Adult | 9 | 2018 | 7880 | 0.410 |
Why?
| | Models, Biological | 2 | 2009 | 408 | 0.410 |
Why?
| | Child Language | 2 | 2017 | 16 | 0.410 |
Why?
| | Qualitative Research | 2 | 2017 | 78 | 0.390 |
Why?
| | Bottle Feeding | 2 | 2016 | 20 | 0.380 |
Why?
| | Anthropometry | 1 | 2005 | 56 | 0.380 |
Why?
| | Bedding and Linens | 2 | 2003 | 5 | 0.370 |
Why?
| | Socioeconomic Factors | 2 | 2017 | 303 | 0.370 |
Why?
| | Carbon Dioxide | 2 | 2003 | 14 | 0.370 |
Why?
| | Polymorphism, Single Nucleotide | 3 | 2017 | 287 | 0.340 |
Why?
| | Retrospective Studies | 6 | 2019 | 2390 | 0.340 |
Why?
| | Prone Position | 1 | 2003 | 10 | 0.320 |
Why?
| | Risk Factors | 4 | 2017 | 2048 | 0.320 |
Why?
| | Motor Activity | 2 | 2017 | 358 | 0.310 |
Why?
| | Incidence | 5 | 2017 | 640 | 0.290 |
Why?
| | Cohort Studies | 5 | 2019 | 1431 | 0.290 |
Why?
| | Respiration | 1 | 2001 | 28 | 0.290 |
Why?
| | Evidence-Based Practice | 3 | 2017 | 65 | 0.290 |
Why?
| | United States | 3 | 2017 | 1840 | 0.280 |
Why?
| | Tissue and Organ Procurement | 2 | 2017 | 30 | 0.260 |
Why?
| | Linear Models | 2 | 2017 | 247 | 0.240 |
Why?
| | Practice Guidelines as Topic | 3 | 2017 | 316 | 0.240 |
Why?
| | Cognition | 2 | 2017 | 824 | 0.240 |
Why?
| | Multivariate Analysis | 2 | 2017 | 338 | 0.240 |
Why?
| | European Continental Ancestry Group | 3 | 2018 | 495 | 0.230 |
Why?
| | Chicago | 3 | 2016 | 731 | 0.230 |
Why?
| | Logistic Models | 2 | 2017 | 429 | 0.230 |
Why?
| | Nod1 Signaling Adaptor Protein | 1 | 2017 | 1 | 0.220 |
Why?
| | Histamine H2 Antagonists | 1 | 2017 | 8 | 0.220 |
Why?
| | Protective Factors | 1 | 2017 | 13 | 0.220 |
Why?
| | Directive Counseling | 1 | 2017 | 10 | 0.210 |
Why?
| | Nutritive Value | 1 | 2017 | 25 | 0.210 |
Why?
| | Oligosaccharides | 1 | 2017 | 16 | 0.210 |
Why?
| | Nutritional Status | 1 | 2017 | 49 | 0.210 |
Why?
| | Probiotics | 1 | 2017 | 20 | 0.210 |
Why?
| | Blood Transfusion | 1 | 2017 | 47 | 0.210 |
Why?
| | Time Factors | 2 | 2018 | 1581 | 0.210 |
Why?
| | Gram-Positive Bacterial Infections | 1 | 2017 | 62 | 0.210 |
Why?
| | Peer Group | 1 | 2017 | 37 | 0.210 |
Why?
| | Return to Work | 1 | 2016 | 24 | 0.210 |
Why?
| | Patient Outcome Assessment | 1 | 2017 | 37 | 0.200 |
Why?
| | Program Evaluation | 1 | 2017 | 129 | 0.200 |
Why?
| | Anemia | 1 | 2017 | 85 | 0.200 |
Why?
| | Bacteremia | 1 | 2017 | 106 | 0.190 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2016 | 31 | 0.190 |
Why?
| | DNA, Bacterial | 1 | 2016 | 51 | 0.190 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2016 | 42 | 0.190 |
Why?
| | Illinois | 1 | 2016 | 205 | 0.190 |
Why?
| | Phylogeny | 1 | 2016 | 76 | 0.190 |
Why?
| | Cost of Illness | 2 | 2013 | 49 | 0.190 |
Why?
| | Chondroitinases and Chondroitin Lyases | 1 | 2015 | 6 | 0.190 |
Why?
| | Transforming Growth Factor beta2 | 1 | 2015 | 13 | 0.190 |
Why?
| | Feces | 1 | 2016 | 85 | 0.190 |
Why?
| | Interviews as Topic | 1 | 2015 | 120 | 0.180 |
Why?
| | Cost Savings | 1 | 2015 | 32 | 0.180 |
Why?
| | Age Factors | 1 | 2017 | 756 | 0.170 |
Why?
| | Adolescent | 3 | 2017 | 2185 | 0.170 |
Why?
| | Retinopathy of Prematurity | 1 | 2014 | 8 | 0.170 |
Why?
| | Diabetes Insipidus, Neurogenic | 1 | 2013 | 3 | 0.170 |
Why?
| | Enterovirus Infections | 1 | 2013 | 4 | 0.170 |
Why?
| | Deamino Arginine Vasopressin | 1 | 2013 | 4 | 0.170 |
Why?
| | Anti-Bacterial Agents | 1 | 2017 | 349 | 0.170 |
Why?
| | Meningoencephalitis | 1 | 2013 | 10 | 0.160 |
Why?
| | Postnatal Care | 1 | 2013 | 7 | 0.160 |
Why?
| | Feeding Methods | 1 | 2013 | 5 | 0.160 |
Why?
| | Pharmacopoeias as Topic | 1 | 2012 | 5 | 0.160 |
Why?
| | Propensity Score | 1 | 2013 | 37 | 0.160 |
Why?
| | Costs and Cost Analysis | 1 | 2013 | 35 | 0.160 |
Why?
| | Cardiovascular Agents | 1 | 2012 | 20 | 0.150 |
Why?
| | Pulmonary Gas Exchange | 2 | 2003 | 7 | 0.150 |
Why?
| | Direct Service Costs | 1 | 2012 | 5 | 0.150 |
Why?
| | Tidal Volume | 2 | 2003 | 9 | 0.150 |
Why?
| | Infant, Newborn, Diseases | 1 | 2012 | 14 | 0.150 |
Why?
| | Sudden Infant Death | 2 | 2003 | 31 | 0.150 |
Why?
| | Hospital Costs | 1 | 2013 | 66 | 0.150 |
Why?
| | Codon, Terminator | 1 | 2011 | 1 | 0.150 |
Why?
| | Toll-Like Receptor 5 | 1 | 2011 | 1 | 0.150 |
Why?
| | Pediatrics | 1 | 2012 | 48 | 0.150 |
Why?
| | Longitudinal Studies | 1 | 2016 | 1080 | 0.150 |
Why?
| | Heart Diseases | 1 | 2012 | 84 | 0.140 |
Why?
| | NF-kappa B p50 Subunit | 1 | 2011 | 1 | 0.140 |
Why?
| | Young Adult | 4 | 2018 | 1652 | 0.130 |
Why?
| | African Americans | 1 | 2016 | 584 | 0.130 |
Why?
| | Fluconazole | 1 | 2010 | 7 | 0.130 |
Why?
| | Cultured Milk Products | 1 | 2009 | 2 | 0.130 |
Why?
| | Milk | 1 | 2009 | 7 | 0.130 |
Why?
| | Mycoses | 1 | 2010 | 20 | 0.130 |
Why?
| | Antibiotic Prophylaxis | 1 | 2010 | 32 | 0.130 |
Why?
| | Antifungal Agents | 1 | 2010 | 38 | 0.130 |
Why?
| | Pilot Projects | 3 | 2018 | 348 | 0.110 |
Why?
| | Diet | 1 | 2009 | 164 | 0.110 |
Why?
| | Predictive Value of Tests | 1 | 2009 | 522 | 0.100 |
Why?
| | Genetic Predisposition to Disease | 3 | 2017 | 384 | 0.100 |
Why?
| | Ventricular Pressure | 1 | 1996 | 3 | 0.100 |
Why?
| | Lidocaine | 1 | 1996 | 34 | 0.100 |
Why?
| | Anti-Arrhythmia Agents | 1 | 1996 | 93 | 0.090 |
Why?
| | Models, Theoretical | 1 | 2005 | 92 | 0.090 |
Why?
| | Ion Channel Gating | 1 | 1996 | 193 | 0.080 |
Why?
| | Respiratory Mechanics | 1 | 2003 | 6 | 0.080 |
Why?
| | Blood Gas Analysis | 1 | 2003 | 9 | 0.080 |
Why?
| | Respiratory Function Tests | 1 | 2003 | 26 | 0.080 |
Why?
| | Face | 1 | 2003 | 16 | 0.080 |
Why?
| | Videotape Recording | 1 | 2003 | 47 | 0.080 |
Why?
| | Child | 3 | 2017 | 1260 | 0.080 |
Why?
| | Polysomnography | 1 | 2003 | 86 | 0.080 |
Why?
| | Case-Control Studies | 2 | 2017 | 555 | 0.080 |
Why?
| | Animals | 4 | 2017 | 4673 | 0.080 |
Why?
| | Air | 1 | 2001 | 7 | 0.070 |
Why?
| | Methods | 1 | 2001 | 26 | 0.070 |
Why?
| | Environment | 1 | 2001 | 55 | 0.070 |
Why?
| | Lymphoproliferative Disorders | 1 | 2001 | 21 | 0.070 |
Why?
| | Organ Transplantation | 1 | 2001 | 29 | 0.070 |
Why?
| | Immunosuppressive Agents | 1 | 2001 | 143 | 0.060 |
Why?
| | Antiviral Agents | 1 | 2001 | 118 | 0.060 |
Why?
| | Maternal Age | 1 | 2018 | 10 | 0.060 |
Why?
| | North Carolina | 1 | 2018 | 11 | 0.060 |
Why?
| | Income | 1 | 2018 | 47 | 0.060 |
Why?
| | Gene Frequency | 1 | 2017 | 83 | 0.050 |
Why?
| | Chi-Square Distribution | 1 | 2017 | 170 | 0.050 |
Why?
| | Risk | 1 | 2017 | 203 | 0.050 |
Why?
| | Odds Ratio | 1 | 2017 | 269 | 0.050 |
Why?
| | Phenotype | 1 | 2017 | 312 | 0.050 |
Why?
| | Tissue Donors | 1 | 2016 | 54 | 0.050 |
Why?
| | Child, Preschool | 2 | 2013 | 698 | 0.050 |
Why?
| | Biomedical Research | 1 | 2016 | 69 | 0.050 |
Why?
| | Macrophage Activation | 1 | 2015 | 11 | 0.050 |
Why?
| | Biological Availability | 1 | 2015 | 24 | 0.050 |
Why?
| | Chondroitin Sulfate Proteoglycans | 1 | 2015 | 45 | 0.050 |
Why?
| | NF-kappa B | 1 | 2015 | 101 | 0.040 |
Why?
| | Recombinant Proteins | 1 | 2015 | 294 | 0.040 |
Why?
| | Cell Line | 1 | 2015 | 334 | 0.040 |
Why?
| | Anti-Inflammatory Agents | 1 | 2015 | 93 | 0.040 |
Why?
| | Morbidity | 1 | 2014 | 52 | 0.040 |
Why?
| | Enterovirus B, Human | 1 | 2013 | 2 | 0.040 |
Why?
| | Ampicillin | 1 | 2013 | 9 | 0.040 |
Why?
| | Gentamicins | 1 | 2013 | 13 | 0.040 |
Why?
| | Risk Assessment | 1 | 2017 | 628 | 0.040 |
Why?
| | Cost-Benefit Analysis | 1 | 2014 | 118 | 0.040 |
Why?
| | Postoperative Complications | 1 | 2001 | 851 | 0.040 |
Why?
| | Organizational Culture | 1 | 2013 | 19 | 0.040 |
Why?
| | Intestinal Mucosa | 1 | 2015 | 201 | 0.040 |
Why?
| | Inflammation | 1 | 2015 | 272 | 0.040 |
Why?
| | Interleukin-1 Receptor-Associated Kinases | 1 | 2011 | 1 | 0.040 |
Why?
| | Cardiology | 1 | 2012 | 69 | 0.040 |
Why?
| | Disease Management | 1 | 2012 | 104 | 0.040 |
Why?
| | Patient Education as Topic | 1 | 2013 | 162 | 0.030 |
Why?
| | Heterozygote | 1 | 2011 | 86 | 0.030 |
Why?
| | Toll-Like Receptors | 1 | 2011 | 25 | 0.030 |
Why?
| | Attitude of Health Personnel | 1 | 2013 | 155 | 0.030 |
Why?
| | Genetic Variation | 1 | 2011 | 105 | 0.030 |
Why?
| | Cholestasis | 1 | 2010 | 12 | 0.030 |
Why?
| | Colostrum | 1 | 2010 | 7 | 0.030 |
Why?
| | Candidiasis | 1 | 2010 | 14 | 0.030 |
Why?
| | Mice | 1 | 2015 | 1588 | 0.030 |
Why?
| | Signal Transduction | 1 | 2011 | 506 | 0.030 |
Why?
| | Prognosis | 1 | 2009 | 797 | 0.030 |
Why?
| | Severity of Illness Index | 1 | 2011 | 1050 | 0.020 |
Why?
| | Chick Embryo | 1 | 1996 | 22 | 0.020 |
Why?
| | Isotonic Solutions | 1 | 1996 | 17 | 0.020 |
Why?
| | Sodium Channels | 1 | 1996 | 15 | 0.020 |
Why?
| | Verapamil | 1 | 1996 | 36 | 0.020 |
Why?
| | Calcium Channel Blockers | 1 | 1996 | 37 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2010 | 2995 | 0.020 |
Why?
| | Lymphoma | 1 | 2001 | 55 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2001 | 245 | 0.020 |
Why?
| | Antineoplastic Agents | 1 | 2001 | 299 | 0.010 |
Why?
|
|
Patel's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|